Cargando…

Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study

OBJECTIVES: There are still challenging problems in diagnosis of hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) before operation. This study aimed to analyze the imaging features of HCC with B1–B3 BDTT. MATERIALS AND METHODS: The clinicopathological data and imaging findings of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jun-Yi, Huang, Li-Ming, Bai, Yan-Nan, Wu, Jia-Yi, Wei, Yong-Gang, Zhang, Zhi-Bo, Yan, Mao-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602699/
https://www.ncbi.nlm.nih.gov/pubmed/34804918
http://dx.doi.org/10.3389/fonc.2021.723455
_version_ 1784601626061832192
author Wu, Jun-Yi
Huang, Li-Ming
Bai, Yan-Nan
Wu, Jia-Yi
Wei, Yong-Gang
Zhang, Zhi-Bo
Yan, Mao-Lin
author_facet Wu, Jun-Yi
Huang, Li-Ming
Bai, Yan-Nan
Wu, Jia-Yi
Wei, Yong-Gang
Zhang, Zhi-Bo
Yan, Mao-Lin
author_sort Wu, Jun-Yi
collection PubMed
description OBJECTIVES: There are still challenging problems in diagnosis of hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) before operation. This study aimed to analyze the imaging features of HCC with B1–B3 BDTT. MATERIALS AND METHODS: The clinicopathological data and imaging findings of 30 HCC patients with B1–B3 BDTT from three high-volume institutions were retrospectively reviewed. A total of 631 patients without BDTT who were randomly collected from each of the enrolled centers were recorded as the control group to analyze the differences in clinicopathological characteristics and imaging features between the two groups. A total of 453 HCC patients who underwent surgical treatment in the three institutions from January 2020 to December 2020 were collected for a blinded reading test as the validation group. RESULTS: HCC patients with B1–B3 BDTT had more advanced tumor stages and adverse clinicopathological features. HCC lesions were detected in all patients, and intrahepatic bile duct dilation was observed in 28 (93.3%) patients with B1–B3 BDTT and 9 (1.43%) patients in HCC without BDTT. The intrahepatic bile duct dilation showed no enhancement at hepatic arterial phase (HAP) and no progressively delayed enhancement at portal venous phase (PVP), but it was more obvious at PVP on CT. In the reports of the 30 HCC patients with B1–B3 BDTT generated for the image when the scan was done, BDTT was observed in all 13 B3 patients and 3 of 12 B2 patients, but none of the 5 B1 patients. Fourteen patients were misdiagnosed before surgery. However, when using intrahepatic bile duct dilation in HCC patients as a potential biomarker for BDTT diagnosis, the sensitivity and specificity for BDTT diagnosis were 93.33% and 98.57%, respectively. The blinded reading test showed that intrahepatic bile duct dilation in CT and MRI scans could be for separating HCC patients with B1–B3 BDTT from HCC patients without BDTT. CONCLUSIONS: The HCC lesions and intrahepatic bile duct dilation on CT or MRI scans are imaging features of HCC with BDTT, which might facilitate the early diagnosis of B1–B3 BDTT.
format Online
Article
Text
id pubmed-8602699
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86026992021-11-20 Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study Wu, Jun-Yi Huang, Li-Ming Bai, Yan-Nan Wu, Jia-Yi Wei, Yong-Gang Zhang, Zhi-Bo Yan, Mao-Lin Front Oncol Oncology OBJECTIVES: There are still challenging problems in diagnosis of hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) before operation. This study aimed to analyze the imaging features of HCC with B1–B3 BDTT. MATERIALS AND METHODS: The clinicopathological data and imaging findings of 30 HCC patients with B1–B3 BDTT from three high-volume institutions were retrospectively reviewed. A total of 631 patients without BDTT who were randomly collected from each of the enrolled centers were recorded as the control group to analyze the differences in clinicopathological characteristics and imaging features between the two groups. A total of 453 HCC patients who underwent surgical treatment in the three institutions from January 2020 to December 2020 were collected for a blinded reading test as the validation group. RESULTS: HCC patients with B1–B3 BDTT had more advanced tumor stages and adverse clinicopathological features. HCC lesions were detected in all patients, and intrahepatic bile duct dilation was observed in 28 (93.3%) patients with B1–B3 BDTT and 9 (1.43%) patients in HCC without BDTT. The intrahepatic bile duct dilation showed no enhancement at hepatic arterial phase (HAP) and no progressively delayed enhancement at portal venous phase (PVP), but it was more obvious at PVP on CT. In the reports of the 30 HCC patients with B1–B3 BDTT generated for the image when the scan was done, BDTT was observed in all 13 B3 patients and 3 of 12 B2 patients, but none of the 5 B1 patients. Fourteen patients were misdiagnosed before surgery. However, when using intrahepatic bile duct dilation in HCC patients as a potential biomarker for BDTT diagnosis, the sensitivity and specificity for BDTT diagnosis were 93.33% and 98.57%, respectively. The blinded reading test showed that intrahepatic bile duct dilation in CT and MRI scans could be for separating HCC patients with B1–B3 BDTT from HCC patients without BDTT. CONCLUSIONS: The HCC lesions and intrahepatic bile duct dilation on CT or MRI scans are imaging features of HCC with BDTT, which might facilitate the early diagnosis of B1–B3 BDTT. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602699/ /pubmed/34804918 http://dx.doi.org/10.3389/fonc.2021.723455 Text en Copyright © 2021 Wu, Huang, Bai, Wu, Wei, Zhang and Yan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wu, Jun-Yi
Huang, Li-Ming
Bai, Yan-Nan
Wu, Jia-Yi
Wei, Yong-Gang
Zhang, Zhi-Bo
Yan, Mao-Lin
Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title_full Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title_fullStr Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title_full_unstemmed Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title_short Imaging Features of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Multicenter Study
title_sort imaging features of hepatocellular carcinoma with bile duct tumor thrombus: a multicenter study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602699/
https://www.ncbi.nlm.nih.gov/pubmed/34804918
http://dx.doi.org/10.3389/fonc.2021.723455
work_keys_str_mv AT wujunyi imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT huangliming imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT baiyannan imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT wujiayi imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT weiyonggang imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT zhangzhibo imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy
AT yanmaolin imagingfeaturesofhepatocellularcarcinomawithbileducttumorthrombusamulticenterstudy